# US 2021/0276992 A1 · Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276992 A1
- Document ID: US20210276992A1
- Status: Published application
- Kind: A1
- Application number: 17/261,982
- Filed: 2019-07-26
- Published: 2021-09-09
- Earliest claimed: 2018-08-01
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Jian Liu; Dane James Clausen; Wensheng Yu; Joseph M. Kelly; Hyunjin M. Kim; Joseph A. Kozlowski
- Web page: https://patentgrep.com/patent/US20210276992A1

## CPC

- A61P 31/18: for HIV
- C07D 413/14: containing three or more hetero rings
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 498/10: Spiro-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

## Claims

### Claim 1

A compound of the formula:
wherein
is a five-membered heteroaryl ring which is optionally substituted with halo, cyano or C1-3 alkyl;
is a five-membered heteroaryl ring which is optionally substituted with C1-3 alkyl;
R1 is phenyl or heteroaryl, which may be monocyclic or bicyclic, wherein said phenyl and heteroaryl groups are optionally substituted with one to three groups independently selected from the group consisting of halo, oxo, cyano, R4, R6, OR4, OR6 and SO2R4;
R2 is selected from the group consisting of hydrogen, NH(C═O)R6, NH(C═O)CH2R6, NH(C═O)R4, NH(C═O)R5, NH(C═O)OR5 NH2, NHR4, NHR6, NHCH2R6 and R6;
R3 is selected from hydrogen or C1-6 alkyl;
or R2 and R3 can be taken together with the atoms to which they are attached to form a 5, 6 or 7 membered heterocyclyl group which is optionally substituted with oxo;
each R4 is independently hydrogen or C1-6 alkyl, which is optionally substituted with one to three halo;
each R5 is independently hydrogen or C1-6 alkyl, which is optionally substituted with N(R4)2 or OR4;
R6 is
(a) heterocyclyl, which may be monocyclic or bicyclic,
(b) C3-6 cycloalkyl,
(c) phenyl, or
(d) heteroaryl, which may be monocyclic or bicyclic,
wherein said heterocyclyl, cycloalkyl, phenyl and heteroaryl groups are optionally substituted with one to two groups independently selected from the group of oxo, R5, OR4 and heteroaryl;
Ra is hydrogen or halo;
Rb is hydrogen or halo;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein
is selected from imidazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazolyl or triazolyl, wherein said groups are optionally substituted with halo, cyano or C1-3 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1 wherein
is selected from isoxazolyl, oxazolyl or thiazolyl, wherein said groups are optionally substituted with C1-3 alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R1 is dishydroisoquinolinyl, imidazolyl, isoquinolinyl, napthyridinyl, phenyl, pyrazinyl, pyridinyl, quinolinyl or quinoxalinyl, wherein said groups are optionally substituted with one to three groups optionally selected from the group consisting of halo, oxo, cyano, R4, R6, OR4, OR6 and SO2R4; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R2 is NH(C═O)R6 or NH(C═O)CH2R6, and R6 is selected from the group consisting of azaindolyl, azaspirononanyl, azaspirooctanyl, azetidinyl, benzisoxazolyl, cyclobutyl, cyclopentyl, cyclopropyl, dihydrobenzodioxinyl, dihydropyrazoloxazinyl, dihydropyrazolyothiazinedioxidyl, dioxanyl, morpholinyl, oxadiazaspirodecenyl, oxaspirooctanyl, oxazolidinonyl, oxazolyl, phenyl, piperazinyl, piperidinyl, pyrazolopyrimidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl and thiazolyl; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R2 is NH2, or a pharmaceutically acceptable salt thereof.

### Claim 7

A compound being one of the compounds numbered 1-196 in the above specification, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

A method for the inhibition of HDAC in a subject in need thereof which comprises administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A method for the treatment of infection by HIV or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the inhibition of HDAC, for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a subject in need thereof.

### Claim 12 (depends on 8)

The pharmaceutical composition of claim 8, further comprising one or more additional therapeutic agents selected from raltegravir, lamivudine, abacavir, ritonavir, darunavir, atazanavir, emtricitabine, tenofovir, rilpivirine, doravirine, EFdA and lopinavir.

### Claim 13 (depends on 10)

The method of claim 10, further comprising administering to the subject one or more additional therapeutic agents selected from raltegravir, lamivudine, abacavir, ritonavir, darunavir, atazanavir, emtricitabine, tenofovir, rilpivirine, doravirine, EFdA and lopinavir, wherein the amounts administered of the compounds are together effective to treat infection by HIV or to treat, prevent or delay the onset or progression of AIDS.

### Claim 14

(canceled)
